Baird reiterates Regeneron stock rating on Sanofi collaboration
Baird reiterated a Neutral rating and $761 price target for Regeneron (NASDAQ:REGN) after its expanded collaboration with Sanofi. The deal could bring Regeneron up to $8 billion in cash and a 50:50 profit share. Analysts from Jefferies, BMO, and Argus raised their price targets, citing the partnership's potential and Dupixent's strong performance.
How this was made
The 30-second read
Why it matters
Analyst upgrades and higher price targets reflect optimism about the partnership's financial upside and litigation settlement.
Market read
The new collaboration could boost Regeneron's revenue outlook, prompting analysts to raise price targets and potentially lift the stock in the short term.
What to watch
Regeneron's reliance on Sanofi's commercialization capabilities and potential regulatory hurdles for the new antibodies.
Background
Regeneron and Sanofi expanded their existing antibody partnership to include long‑acting IL‑13, IL‑4, and IL‑4Rα antibodies, with a profit‑share structure and up to $8 billion in cash potential.
Ticker impact
Baird reiterated a Neutral rating and raised the price target to $761 after Regeneron expanded its antibody collaboration with Sanofi, adding up to $8 billion in potential cash and profit sharing.
likely upward pressure as investors price in the expanded partnership and cash upside.
The collaboration adds significant revenue upside and resolves litigation, which analysts view as a catalyst for share appreciation.
Market effects
Biotech sector may benefit from renewed partnership activity, potentially lifting peers with similar collaboration models.
U.S. biotech stocks could see modest gains in early trading.
Limited to companies involved in antibody collaborations; no broad macro impact.
Counterpoint
The partnership may not translate into near‑term revenue if development timelines slip, keeping the stock range‑bound.
Key entities
- companyRegeneron Pharmaceuticals
US‑listed biotech firm (NASDAQ:REGN) expanding its collaboration with Sanofi.
- companySanofi
French pharma partner in the expanded antibody collaboration.
